Two doctors of pharmacy review the impact of recent outcomes trials for newer classes of type 2 diabetes therapy.
Joseph E. Cruz, PharmD, BCPS
Advertisement
Articles by Joseph E. Cruz, PharmD, BCPS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
2
First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention
3
Social Factors May Match, Outpace Genetic Risk in Disease Prediction
4
Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC
5